{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T10:05:23Z","timestamp":1792317923846,"version":"4.4.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T00:00:00Z","timestamp":1583452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T00:00:00Z","timestamp":1583452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Angiotensin-[1\u20137] (Ang-[1\u20137]) antagonize the actions of the renin-angiotensin-system via the Mas receptor and thereby exert renoprotective effects. Murine recombinant angiotensin-converting enzyme (ACE)2 was reported to show renoprotective effects in an experimental Alport syndrome model; however, the protective effect of direct administration of Ang-[1\u20137] is unknown. Here, we used\n                    <jats:italic>Col4a3<\/jats:italic>\n                    <jats:sup>\u2212\/\u2212<\/jats:sup>\n                    mice as a model of Alport syndrome, which were treated with saline or Ang- [1\u20137]; saline-treated wild-type mice were used as a control group. The mice were continuously infused with saline or Ang-[1\u20137] (25\u2009\u03bcg\/kg\/h) using osmotic mini-pumps.\n                    <jats:italic>Col4a3<\/jats:italic>\n                    <jats:sup>\u2212\/\u2212<\/jats:sup>\n                    mice showed increased \u03b1-smooth muscle actin (SMA), collagen, and fibronectin expression levels, which were attenuated by Ang-[1\u20137] treatment. Moreover, Ang-[1\u20137] alleviated activation of transforming growth factor-\u03b2\/Smad signaling, and attenuated the protein expression of ED-1 and heme oxygenase-1, indicating reduction of renal inflammation. Ang-[1\u20137] treatment further reduced the expression levels of inflammatory cytokines and adhesion molecules and attenuated apoptosis in human kidney cells. Finally, Ang-[1\u20137] downregulated TNF-\u03b1 converting enzyme and upregulated ACE2 expression. Thus, treatment with Ang-[1\u20137] altered the ACE2-Ang-[1\u20137]-Mas receptor axis in the kidneys of\n                    <jats:italic>Col4a3<\/jats:italic>\n                    <jats:sup>\u2212\/\u2212<\/jats:sup>\n                    mice to attenuate the nephropathy progression of Alport syndrome.\n                  <\/jats:p>","DOI":"10.1038\/s41598-020-61250-5","type":"journal-article","created":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T06:02:37Z","timestamp":1583474557000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Angiotensin-[1\u20137] attenuates kidney injury in experimental Alport syndrome"],"prefix":"10.1038","volume":"10","author":[{"given":"Hong Sang","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Seong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong Kwon","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Scholey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Wan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Hui","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,6]]},"reference":[{"key":"61250_CR1","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nrneph.2012.281","volume":"9","author":"HJ Lambers Heerspink","year":"2013","unstructured":"Lambers Heerspink, H. J., de Borst, M. H., Bakker, S. J. & Navis, G. J. Improving the efficacy of RAAS blockade in patients with chronic kidney disease. Nature reviews. Nephrology 9, 112\u2013121, https:\/\/doi.org\/10.1038\/nrneph.2012.281 (2013).","journal-title":"Nature reviews. Nephrology"},{"key":"61250_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/kisup.2012.66","volume":"3","author":"Chapter 3: Management of progression and complications of CKD","year":"2013","unstructured":"Chapter 3: Management of progression and complications of CKD. Kidney international supplements 3, 73\u201390, https:\/\/doi.org\/10.1038\/kisup.2012.66 (2013).","journal-title":"Kidney international supplements"},{"key":"61250_CR3","doi-asserted-by":"publisher","first-page":"F579","DOI":"10.1152\/ajprenal.00548.2009","volume":"298","author":"J Zhang","year":"2010","unstructured":"Zhang, J., Noble, N. A., Border, W. A. & Huang, Y. Infusion of angiotensin-(1\u20137) reduces glomerulosclerosis through counteracting angiotensin II in experimental glomerulonephritis. American journal of physiology. Renal physiology 298, F579\u2013588, https:\/\/doi.org\/10.1152\/ajprenal.00548.2009 (2010).","journal-title":"American journal of physiology. Renal physiology"},{"key":"61250_CR4","doi-asserted-by":"publisher","first-page":"e0142664","DOI":"10.1371\/journal.pone.0142664","volume":"10","author":"CS Kim","year":"2015","unstructured":"Kim, C. S. et al. Angiotensin-(1\u20137) Attenuates Kidney Injury Due to Obstructive Nephropathy in Rats. PloS one 10, e0142664, https:\/\/doi.org\/10.1371\/journal.pone.0142664 (2015).","journal-title":"PloS one"},{"key":"61250_CR5","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1136\/bmj.1.3454.504","volume":"1","author":"AC Alport","year":"1927","unstructured":"Alport, A. C. Hereditary Familial Congenital Haemorrhagic Nephritis. British medical journal 1, 504\u2013506, https:\/\/doi.org\/10.1136\/bmj.1.3454.504 (1927).","journal-title":"British medical journal"},{"key":"61250_CR6","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/S0140-6736(88)90753-2","volume":"2","author":"FA Flinter","year":"1988","unstructured":"Flinter, F. A., Cameron, J. S., Chantler, C., Houston, I. & Bobrow, M. Genetics of classic Alport\u2019s syndrome. Lancet 2, 1005\u20131007 (1988).","journal-title":"Lancet"},{"key":"61250_CR7","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/S0272-6386(99)70385-9","volume":"34","author":"A Remuzzi","year":"1999","unstructured":"Remuzzi, A., Fassi, A., Bertani, T., Perico, N. & Remuzzi, G. ACE inhibition induces regression of proteinuria and halts progression of renal damage in a genetic model of progressive nephropathy. American journal of kidney diseases: the official journal of the National Kidney Foundation 34, 626\u2013632, https:\/\/doi.org\/10.1016\/S0272-6386(99)70385-9 (1999).","journal-title":"American journal of kidney diseases: the official journal of the National Kidney Foundation"},{"key":"61250_CR8","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1046\/j.1523-1755.2003.00779.x","volume":"63","author":"O Gross","year":"2003","unstructured":"Gross, O. et al. Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome. Kidney international 63, 438\u2013446, https:\/\/doi.org\/10.1046\/j.1523-1755.2003.00779.x (2003).","journal-title":"Kidney international"},{"key":"61250_CR9","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1093\/ndt\/gfh219","volume":"19","author":"O Gross","year":"2004","unstructured":"Gross, O. et al. Antifibrotic, nephroprotective potential of ACE inhibitor vs AT1 antagonist in a murine model of renal fibrosis. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association 19, 1716\u20131723, https:\/\/doi.org\/10.1093\/ndt\/gfh219 (2004).","journal-title":"Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association"},{"key":"61250_CR10","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00467-012-2372-9","volume":"28","author":"NJ Webb","year":"2013","unstructured":"Webb, N. J. et al. Losartan and enalapril are comparable in reducing proteinuria in children with Alport syndrome. Pediatric nephrology 28, 737\u2013743, https:\/\/doi.org\/10.1007\/s00467-012-2372-9 (2013).","journal-title":"Pediatric nephrology"},{"key":"61250_CR11","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1681\/ASN.2012020148","volume":"24","author":"J Savige","year":"2013","unstructured":"Savige, J. et al. Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy. Journal of the American Society of Nephrology: JASN 24, 364\u2013375, https:\/\/doi.org\/10.1681\/ASN.2012020148 (2013).","journal-title":"Journal of the American Society of Nephrology: JASN"},{"key":"61250_CR12","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1101\/gad.10.23.2981","volume":"10","author":"D Cosgrove","year":"1996","unstructured":"Cosgrove, D. et al. Collagen COL4A3 knockout: a mouse model for autosomal Alport syndrome. Genes & development 10, 2981\u20132992, https:\/\/doi.org\/10.1101\/gad.10.23.2981 (1996).","journal-title":"Genes & development"},{"key":"61250_CR13","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/j.ajpath.2015.01.021","volume":"185","author":"EH Bae","year":"2015","unstructured":"Bae, E. H. et al. Characterization of the intrarenal renin-angiotensin system in experimental alport syndrome. The American journal of pathology 185, 1423\u20131435, https:\/\/doi.org\/10.1016\/j.ajpath.2015.01.021 (2015).","journal-title":"The American journal of pathology"},{"key":"61250_CR14","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.kint.2016.12.022","volume":"91","author":"EH Bae","year":"2017","unstructured":"Bae, E. H. et al. Murine recombinant angiotensin-converting enzyme 2 attenuates kidney injury in experimental Alport syndrome. Kidney international 91, 1347\u20131361, https:\/\/doi.org\/10.1016\/j.kint.2016.12.022 (2017).","journal-title":"Kidney international"},{"key":"61250_CR15","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s10157-018-1629-4","volume":"23","author":"K Nozu","year":"2019","unstructured":"Nozu, K. et al. A review of clinical characteristics and genetic backgrounds in Alport syndrome. Clinical and experimental nephrology 23, 158\u2013168, https:\/\/doi.org\/10.1007\/s10157-018-1629-4 (2019).","journal-title":"Clinical and experimental nephrology"},{"key":"61250_CR16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.yjmcc.2013.11.017","volume":"66","author":"VB Patel","year":"2014","unstructured":"Patel, V. B. et al. Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE\/ADAM-17: a positive feedback mechanism in the RAS. Journal of molecular and cellular cardiology 66, 167\u2013176, https:\/\/doi.org\/10.1016\/j.yjmcc.2013.11.017 (2014).","journal-title":"Journal of molecular and cellular cardiology"},{"key":"61250_CR17","doi-asserted-by":"publisher","first-page":"H137","DOI":"10.1152\/ajpheart.00618.2015","volume":"310","author":"MC Chappell","year":"2016","unstructured":"Chappell, M. C. Biochemical evaluation of the renin-angiotensin system: the good, bad, and absolute? American journal of physiology. Heart and circulatory physiology 310, H137\u2013152, https:\/\/doi.org\/10.1152\/ajpheart.00618.2015 (2016).","journal-title":"American journal of physiology. Heart and circulatory physiology"},{"key":"61250_CR18","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.phrs.2016.03.018","volume":"107","author":"ESAC Simoes","year":"2016","unstructured":"Simoes, E. S. A. C. & Teixeira, M. M. ACE inhibition, ACE2 and angiotensin-(1\u20137) axis in kidney and cardiac inflammation and fibrosis. Pharmacological research 107, 154\u2013162, https:\/\/doi.org\/10.1016\/j.phrs.2016.03.018 (2016).","journal-title":"Pharmacological research"},{"key":"61250_CR19","doi-asserted-by":"publisher","first-page":"1841046","DOI":"10.1155\/2018\/1841046","volume":"2018","author":"AM Papinska","year":"2018","unstructured":"Papinska, A. M. & Rodgers, K. E. Long-Term Administration of Angiotensin (1\u20137) to db\/db Mice Reduces Oxidative Stress Damage in the Kidneys and Prevents Renal Dysfunction. Oxidative medicine and cellular longevity 2018, 1841046, https:\/\/doi.org\/10.1155\/2018\/1841046 (2018).","journal-title":"Oxidative medicine and cellular longevity"},{"key":"61250_CR20","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1016\/j.cellsig.2014.09.010","volume":"26","author":"EM Alzayadneh","year":"2014","unstructured":"Alzayadneh, E. M. & Chappell, M. C. Angiotensin-(1\u20137) abolishes AGE-induced cellular hypertrophy and myofibroblast transformation via inhibition of ERK1\/2. Cellular signalling 26, 3027\u20133035, https:\/\/doi.org\/10.1016\/j.cellsig.2014.09.010 (2014).","journal-title":"Cellular signalling"},{"key":"61250_CR21","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1046\/j.1523-1755.1999.00744.x","volume":"56","author":"R Sayers","year":"1999","unstructured":"Sayers, R. et al. Role for transforming growth factor-beta1 in alport renal disease progression. Kidney international 56, 1662\u20131673, https:\/\/doi.org\/10.1046\/j.1523-1755.1999.00744.x (1999).","journal-title":"Kidney international"},{"key":"61250_CR22","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1053\/j.ackd.2005.07.011","volume":"12","author":"AA Eddy","year":"2005","unstructured":"Eddy, A. A. Progression in chronic kidney disease. Advances in chronic kidney disease 12, 353\u2013365, https:\/\/doi.org\/10.1053\/j.ackd.2005.07.011 (2005).","journal-title":"Advances in chronic kidney disease"},{"key":"61250_CR23","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/ki.2010.373","volume":"79","author":"M Ryu","year":"2011","unstructured":"Ryu, M. et al. Bacterial CpG-DNA accelerates Alport glomerulosclerosis by inducing an M1 macrophage phenotype and tumor necrosis factor-alpha-mediated podocyte loss. Kidney international 79, 189\u2013198, https:\/\/doi.org\/10.1038\/ki.2010.373 (2011).","journal-title":"Kidney international"},{"key":"61250_CR24","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/path.2979","volume":"226","author":"M Ryu","year":"2012","unstructured":"Ryu, M., Mulay, S. R., Miosge, N., Gross, O. & Anders, H. J. Tumour necrosis factor-alpha drives Alport glomerulosclerosis in mice by promoting podocyte apoptosis. The Journal of pathology 226, 120\u2013131, https:\/\/doi.org\/10.1002\/path.2979 (2012).","journal-title":"The Journal of pathology"},{"issue":"15","key":"61250_CR25","doi-asserted-by":"publisher","first-page":"3843","DOI":"10.3390\/ijms20153843","volume":"20","author":"Suh","year":"2019","unstructured":"Suh, S. H. et al. Olmesartan Attenuates Kidney Fibrosis in a Murine Model of Alport Syndrome by Suppressing Tubular Expression of TGFbeta. International journal of molecular sciences 20, https:\/\/doi.org\/10.3390\/ijms20153843 (2019).","journal-title":"International Journal of Molecular Sciences"},{"key":"61250_CR26","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1161\/01.hyp.38.1.95","volume":"38","author":"B Tom","year":"2001","unstructured":"Tom, B., de Vries, R., Saxena, P. R. & Danser, A. H. Bradykinin potentiation by angiotensin-(1\u20137) and ACE inhibitors correlates with ACE C- and N-domain blockade. Hypertension 38, 95\u201399, https:\/\/doi.org\/10.1161\/01.hyp.38.1.95 (2001).","journal-title":"Hypertension"},{"key":"61250_CR27","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1161\/01.HYP.0000124667.34652.1a","volume":"43","author":"Y Ishiyama","year":"2004","unstructured":"Ishiyama, Y. et al. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 43, 970\u2013976, https:\/\/doi.org\/10.1161\/01.HYP.0000124667.34652.1a (2004).","journal-title":"Hypertension"},{"key":"61250_CR28","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1291\/hypres.29.865","volume":"29","author":"J Agata","year":"2006","unstructured":"Agata, J. et al. Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme. Hypertension research: official journal of the Japanese Society of Hypertension 29, 865\u2013874, https:\/\/doi.org\/10.1291\/hypres.29.865 (2006).","journal-title":"Hypertension research: official journal of the Japanese Society of Hypertension"},{"key":"61250_CR29","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1161\/ATVBAHA.113.301320","volume":"33","author":"JM Yang","year":"2013","unstructured":"Yang, J. M. et al. Angiotensin-(1\u20137) dose-dependently inhibits atherosclerotic lesion formation and enhances plaque stability by targeting vascular cells. Arteriosclerosis, thrombosis, and vascular biology 33, 1978\u20131985, https:\/\/doi.org\/10.1161\/ATVBAHA.113.301320 (2013).","journal-title":"Arteriosclerosis, thrombosis, and vascular biology"},{"key":"61250_CR30","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1161\/HYPERTENSIONAHA.115.06935","volume":"67","author":"IM Williams","year":"2016","unstructured":"Williams, I. M. et al. Chronic Angiotensin-(1\u20137) Improves Insulin Sensitivity in High-Fat Fed Mice Independent of Blood Pressure. Hypertension 67, 983\u2013991, https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.115.06935 (2016).","journal-title":"Hypertension"},{"key":"61250_CR31","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1161\/HYPERTENSIONAHA.114.03415","volume":"64","author":"RA Pena Silva","year":"2014","unstructured":"Pena Silva, R. A. et al. Angiotensin 1\u20137 reduces mortality and rupture of intracranial aneurysms in mice. Hypertension 64, 362\u2013368, https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.114.03415 (2014).","journal-title":"Hypertension"},{"key":"61250_CR32","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/bph.13742","volume":"174","author":"SS Karnik","year":"2017","unstructured":"Karnik, S. S., Singh, K. D., Tirupula, K. & Unal, H. Significance of angiotensin 1\u20137 coupling with MAS1 receptor and other GPCRs to the renin-angiotensin system: IUPHAR Review 22. British journal of pharmacology 174, 737\u2013753, https:\/\/doi.org\/10.1111\/bph.13742 (2017).","journal-title":"British journal of pharmacology"},{"key":"61250_CR33","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/ki.2014.274","volume":"87","author":"K Zhang","year":"2015","unstructured":"Zhang, K. et al. Angiotensin(1\u20137) attenuates the progression of streptozotocin-induced diabetic renal injury better than angiotensin receptor blockade. Kidney international 87, 359\u2013369, https:\/\/doi.org\/10.1038\/ki.2014.274 (2015).","journal-title":"Kidney international"},{"key":"61250_CR34","doi-asserted-by":"publisher","first-page":"108","DOI":"10.4068\/cmj.2013.49.3.108","volume":"49","author":"SK Ma","year":"2013","unstructured":"Ma, S. K. et al. Increased Phosphorylation of PI3K\/Akt\/mTOR in the Obstructed Kidney of Rats with Unilateral Ureteral Obstruction. Chonnam medical journal 49, 108\u2013112, https:\/\/doi.org\/10.4068\/cmj.2013.49.3.108 (2013).","journal-title":"Chonnam medical journal"},{"key":"61250_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-30008-5","volume":"8","author":"HS Choi","year":"2018","unstructured":"Choi, H. S. et al. Histone deacetylase inhibitor, CG200745 attenuates renal fibrosis in obstructive kidney disease. Scientific reports 8, 11546, https:\/\/doi.org\/10.1038\/s41598-018-30008-5 (2018).","journal-title":"Scientific reports"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-61250-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-61250-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-61250-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T02:52:48Z","timestamp":1670295168000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-61250-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,6]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["61250"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-61250-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,6]]},"assertion":[{"value":"21 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4225"}}